Trial Profile
A Phase II Trial of Sunitinib in the Treatment of Recurrent Malignant Glioma.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Anaplastic astrocytoma; Astrocytoma; Glioblastoma; Glioma; Gliosarcoma; Oligodendroglioma
- Focus Therapeutic Use
- 22 Jun 2012 Actual patient number 84 added according to ClinicalTrials.gov.
- 22 Jun 2012 Actual patient number 84 added according to ClinicalTrials.gov.
- 22 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov